Serum albumin is associated with the inherent property of acute myeloid leukemia and correlates with patient outcomes
Open Access
- 1 April 2024
- journal article
- research article
- Published by Wolters Kluwer Health in Blood Science
- Vol. 6 (2) , e00189
Abstract
An accurate prognostic model for acute myeloid leukemia (AML) can guide personalized treatment. In our prospective cohort of 591 patients newly diagnosed with AML, we evaluated the prognostic significance of serum albumin levels. We recognized baseline serum albumin as a prognostic factor by univariate Cox regression analysis (albumin-high vs albumin-low: overall survival [OS]: hazard ratio [HR]: 0.679, 95% confidence interval [CI]: 0.529–0.870, P = .002; cumulative incidence of relapse [CIR]: HR: 0.705, 95% CI: 0.530–0.938, P = .017) and multivariate Cox regression analysis (OS: HR per g/L: 0.966, 95% CI: 0.940–0.993, P = .014; CIR: HR per g/L: 0.959, 95% CI: 0.927–0.993, P = .017). In the subgroup analysis, serum albumin was prognostic significant in patients who received intermediate-dose cytarabine combined with daunorubicin and omacetaxine mepesuccinate induction (albumin-high vs albumin-low: OS: HR: 0.585, 95% CI: 0.397–0.863, P = .007; CIR: HR: 0.551, 95% CI: 0.353–0.861, P = .009) rather than those receiving conventional-dose induction regimens. In addition, the impact of baseline serum albumin level was evident in patients with intermediate European LeukemiaNet risk (albumin-high vs albumin-low: OS: HR: 0.617, 95% CI: 0.424–0.896, P = .011; CIR: HR: 0.617, 95% CI: 0.388–0.979, P = .040). Gene set enrichment analysis revealed that leukemia stem cell signatures were enriched in patients with low serum albumin levels. Our study suggested that baseline serum albumin level was associated with the inherent properties of AML and correlated with patient outcomes.Keywords
This publication has 27 references indexed in Scilit:
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panelBlood, 2017
- Serum albumin level at diagnosis of diffuse large B‐cell lymphoma: an important simple prognostic factorHematological Oncology, 2015
- Survival and cure of acute myeloid leukaemia in England, 1971‐2006: a population–based studyBritish Journal of Haematology, 2013
- Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromesAmerican Journal of Hematology, 2012
- Human serum albumin: From bench to bedsideMolecular Aspects of Medicine, 2012
- Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3Blood, 2011
- Severe Hypoalbuminemia at Day 90 Predicts Worse Nonrelapse Mortality and Overall Survival after Allogeneic Hematopoietic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic SyndromeTransplantation and Cellular Therapy, 2011
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNetBlood, 2010
- Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete RemissionJAMA, 2009
- Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high‐risk myelodysplastic syndrome:Cancer, 2006